Literature DB >> 22157415

Castleman disease and associated autoimmune disease.

Theresa W Muskardin1, Bruce A Peterson, Jerry A Molitor.   

Abstract

PURPOSE OF REVIEW: Castleman disease can occur in association with autoimmune connective tissue disease and confound the clinical picture, resulting in delayed diagnosis and suboptimal treatment. This review focuses on the intersection of Castleman disease and autoimmunity with an emphasis on shared pathology and mutually beneficial treatments. RECENT
FINDINGS: Targeting CD-20, interleukin-6, and the nuclear factor-κB pathway has shown promise in achieving long-term remission in patients with Castleman disease and associated autoimmune features.
SUMMARY: Advances in understanding of pathogenic cell types and cytokines in Castleman disease have allowed the development of targeted therapies successful in the treatment of both Castleman disease and associated autoimmune disease.

Entities:  

Mesh:

Year:  2012        PMID: 22157415     DOI: 10.1097/BOR.0b013e32834db525

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  16 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Unicentric Castleman's disease: an uncommon cause of posterior mediastinal mass.

Authors:  Aliasghar Alavi; Mehrnaz Asadi Gharabaghi
Journal:  BMJ Case Rep       Date:  2013-06-11

3.  Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.

Authors:  Dao-Ping Sun; Wen-Ming Chen; Li Wang; Zhen Wang; Jin-Hua Liang; Hua-Yuan Zhu; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

4.  Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.

Authors:  Lauro Ortega; Chad J Cooper; Salman Otoukesh; Mona Mojtahedzadeh; Claudia S Didia; Alireza Torabi; Zeina Nahleh
Journal:  Rare Tumors       Date:  2014-08-06

5.  Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report.

Authors:  Vikram R Rao; Leland E Lim; Dean Fong; Nina I Garga; Karen L Parko
Journal:  BMC Neurol       Date:  2015-02-04       Impact factor: 2.474

6.  Intra-abdominal localized hyaline-vascular Castleman disease: imaging characteristics and management of a rare condition.

Authors:  Nikolaos Vassos; Dimitrios Raptis; Michael Lell; Peter Klein; Aristotelis Perrakis; Jens Köhler; Roland S Croner; Werner Hohenberger; Abbas Agaimy
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

Review 7.  Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease.

Authors:  Anne Musters; Amira Assaf; Danielle M Gerlag; Paul P Tak; Sander W Tas
Journal:  Front Immunol       Date:  2015-12-11       Impact factor: 7.561

8.  Retroperitoneal Castleman's disease: advocating a multidisciplinary approach for a rare clinical entity.

Authors:  Austin D Williams; Adriana Sanchez; Jun Steve Hou; Rene Rothstein Rubin; Mark E Hysell; Blake D Babcock; Mohammad F Shaikh; Michael S Weingarten; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2014-02-04       Impact factor: 2.754

9.  Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease.

Authors:  Feng Li; Xiaomei Zhang; Yanting Guo; Yuandong Zhu; Yicun Wu; Yun Ling
Journal:  Case Rep Hematol       Date:  2018-01-23

10.  Unicentric mixed variant Castleman disease associated with intrabronchial plasmacytoma.

Authors:  Noémi Eszes; Lilla Tamási; Attila Csekeő; Judit Csomor; Agota Szepesi; Gergely Varga; György Balázs; György Losonczy; Veronika Müller
Journal:  Diagn Pathol       Date:  2014-03-20       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.